Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | SORD | Q00796 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365334 | 0.85 | CHRM4 (0.48) | GPBAR1FFAR4HRH3 | |
| Trifluoroacetic Acid SCHEMBL1026901 | 0.83 | FFAR4 (0.51) | LSSFFAR4HRH4HRH3 | |
| SCHEMBL4354310 | 0.81 | MEN1 (0.40) | DGAT1 | |
| SCHEMBL1024330 | 0.81 | ALDH1A1 (0.52) | HRH3GPR119 | |
| SCHEMBL1025550 | 0.80 | FFAR1 (0.44) | FFAR4HRH3DGAT1CKS1BSKP1 | |
| SCHEMBL13622645 | 0.80 | LSS (0.49) | LSSGPBAR1F10FFAR4DGAT1 | |
| SCHEMBL1026902 | 0.80 | HRH3 (0.41) | LSSGPBAR1HRH4HRH3GPR119 | |
| SCHEMBL1024883 | 0.79 | HTR3E (0.48) | FFAR4HRH3DGAT1CKS1BSKP1 | |
| SCHEMBL1023389 | 0.79 | KDM4E (0.50) | GPR119 | |
| Acetic Acid SCHEMBL1026900 | 0.79 | HRH3 (0.43) | LSSHRH4HRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | LSS 2739/4885GPBAR1 2143/4885F10 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.